BackShanghai Labway Clinical Laboratory , Ltd. Overview

Shanghai Labway Clinical Laboratory , Ltd. EBIT

Latest ebit for 301060.SZ: $88M, below the sector sector average of $2.4T.

Get informed when a big investor buys or sells

+ Follow

Quarterly EBIT

$13.86M
↓ 26.78% YoY

As of Sep 30, 2026

Annual EBIT (TTM)

$87.90M
↑ 1066.53% YoY

Trailing 12 months ending Sep 30, 2026

Average EBIT (Comparison Companies)

EBIT History

EBIT Comparison

Annual EBIT Growth Rate (%)

Annual EBIT Growth (Absolute)

Shanghai Labway Clinical Laboratory , Ltd. (301060.SZ) FAQ

As of the most recent data (September 2026), 301060.SZ shows a EBIT of $88M. That compares with $-9.1M in the prior-year period — up 1066.5% year over year. That is below the sector sector average of $2.4T. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, 301060.SZ's EBIT is now $88M (was $-9.1M) — a 1066.5% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Shanghai Labway Clinical Laboratory , Ltd. is outperforming or lagging.

The its sector sector average EBIT is about $2.4T. Shanghai Labway Clinical Laboratory , Ltd. is at $88M, which is lower that average. That is roughly 100.0% below the sector mean. Use the comparison chart on this page to see how 301060.SZ stacks up against individual peers as well.

Tracking 301060.SZ's ebit over time shows whether Shanghai Labway Clinical Laboratory , Ltd. is scaling, shrinking, or reshaping that part of the business. The current reading is $88M That compares with $-9.1M in the prior-year period — up 1066.5% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this ebit page, Stockcircle has Shanghai Labway Clinical Laboratory , Ltd.'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect EBIT (currently $88M) with ownership activity and broader fundamentals.